CRISPR/Cas9-mediated Knockout of C-REL in HeLa Cells Results in Profound Defects of the Cell Cycle
Overview
Authors
Affiliations
Cervical cancer is the fourth common cancer in women resulting worldwide in 266,000 deaths per year. Belonging to the carcinomas, new insights into cervical cancer biology may also have great implications for finding new treatment strategies for other kinds of epithelial cancers. Although the transcription factor NF-κB is known as a key player in tumor formation, the relevance of its particular subunits is still underestimated. Here, we applied CRISPR/Cas9n-mediated genome editing to successfully knockout the NF-κB subunit c-REL in HeLa Kyoto cells as a model system for cervical cancers. We successfully generated a homozygous deletion in the c-REL gene, which we validated using sequencing, qPCR, immunocytochemistry, western blot analysis, EMSA and analysis of off-target effects. On the functional level, we observed the deletion of c-REL to result in a significantly decreased cell proliferation in comparison to wildtype (wt) without affecting apoptosis. The impaired proliferative behavior of c-REL-/- cells was accompanied by a strongly decreased amount of the H2B protein as well as a significant delay in the prometaphase of mitosis compared to c-REL+/+ HeLa Kyoto cells. c-REL-/- cells further showed significantly decreased expression levels of c-REL target genes in comparison to wt. In accordance to our proliferation data, we observed the c-REL knockout to result in a significantly increased resistance against the chemotherapeutic agents 5-Fluoro-2'-deoxyuridine (5-FUDR) and cisplatin. In summary, our findings emphasize the importance of c-REL signaling in a cellular model of cervical cancer with direct clinical implications for the development of new treatment strategies.
Serum Induces the Subunit-Specific Activation of NF-κB in Proliferating Human Cardiac Stem Cells.
Schmidt K, Hoving A, Nowak K, An Mey N, Kiani Zahrani S, Nemeita B Int J Mol Sci. 2024; 25(7).
PMID: 38612406 PMC: 11012129. DOI: 10.3390/ijms25073593.
Impact of Knockout by CRISPR/Cas9 on the MCF-7, HCA-7 and UM-RC-6 Cancer Cells.
Javadi M, Sazegar H, Doosti A Iran J Biotechnol. 2024; 20(4):e3115.
PMID: 38344320 PMC: 10858368. DOI: 10.30498/ijb.2022.298496.3115.
Ten Years of CRISPRing Cancers In Vitro.
Capoferri D, Filiberti S, Faletti J, Tavani C, Ronca R Cancers (Basel). 2022; 14(23).
PMID: 36497228 PMC: 9738354. DOI: 10.3390/cancers14235746.
CRISPR/Cas9: A revolutionary genome editing tool for human cancers treatment.
Akram F, Ul Haq I, Sahreen S, Nasir N, Naseem W, Imitaz M Technol Cancer Res Treat. 2022; 21:15330338221132078.
PMID: 36254536 PMC: 9580090. DOI: 10.1177/15330338221132078.
NF-кB c-Rel modulates pre-fibrotic changes in human fibroblasts.
Micus L, Trautschold-Krause F, Jelit A, Schon M, Lorenz V Arch Dermatol Res. 2021; 314(10):943-951.
PMID: 34888734 PMC: 9522690. DOI: 10.1007/s00403-021-02310-2.